These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 17619167)
1. Marked thrombocytosis during treatment with ceftazidime for pulmonary infection. Chen HC; Wang CY; Wang CS Pharm World Sci; 2008 Jan; 30(1):70-2. PubMed ID: 17619167 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections. Huang CK; Chen YS; Lee SS; Lin WR; Tsai HC; Lin HH; Wann SR; Chen JY; Yen MY; Liu YC J Microbiol Immunol Infect; 2002 Sep; 35(3):159-67. PubMed ID: 12380788 [TBL] [Abstract][Full Text] [Related]
4. Thrombocytosis: an acute-phase reactant, not an adverse reaction to the new beta-lactam antibiotics. Parry MF; Jacobs B; Scully B; Neu HC Diagn Microbiol Infect Dis; 1984 Jun; 2(3):229-31. PubMed ID: 6744802 [TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection. Colardyn F J Chemother; 1995 Jun; 7 Suppl 2():129-35. PubMed ID: 8622101 [TBL] [Abstract][Full Text] [Related]
6. Clinical experience in the treatment of lower respiratory tract infections with ceftazidime. Pettersson T; Ahvonen P; Storgårds E J Antimicrob Chemother; 1981 Sep; 8 Suppl B():303-5. PubMed ID: 19803003 [TBL] [Abstract][Full Text] [Related]
12. Comparison of treatment with imipenem vs. ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: a historical cohort study. Carmeli Y; Samore MH Clin Infect Dis; 1997 Jun; 24(6):1131-4. PubMed ID: 9195070 [TBL] [Abstract][Full Text] [Related]
13. Agranulocytosis, plasmacytosis, and thrombocytosis followed by a leukemoid reaction due to acute acetaminophen toxicity. Gürsoy M; Haznedaroğlu IC; Celik I; Sayinalp N; Ozcebe OI; Dündar SV Ann Pharmacother; 1996; 30(7-8):762-5. PubMed ID: 8826556 [TBL] [Abstract][Full Text] [Related]
14. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Boselli E; Breilh D; Rimmelé T; Poupelin JC; Saux MC; Chassard D; Allaouchiche B Intensive Care Med; 2004 May; 30(5):989-91. PubMed ID: 14985960 [TBL] [Abstract][Full Text] [Related]
15. Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime. Finch RG; Pemberton K; Gildon KM J Chemother; 1998 Feb; 10(1):35-46. PubMed ID: 9531074 [TBL] [Abstract][Full Text] [Related]
16. A Review and Assessment of Drug-Induced Thrombocytosis. Vo QT; Thompson DF Ann Pharmacother; 2019 May; 53(5):523-536. PubMed ID: 30525921 [TBL] [Abstract][Full Text] [Related]
17. To the editor: adverse effects of ceftazidime treatment. Döring G; Heijerman HG Pediatr Pulmonol; 2002 Dec; 34(6):496-7. PubMed ID: 12422350 [No Abstract] [Full Text] [Related]
19. [Tolerance and efficacy of ceftazidime in combination with aztreonam for exacerbations of cystic fibrosis]. Prévotat A; Leroy S; Perez T; Wallet F; Wallaert B Rev Mal Respir; 2010 May; 27(5):449-56. PubMed ID: 20569877 [TBL] [Abstract][Full Text] [Related]
20. Cefepime versus ceftazidime: considerations for empirical use in critically ill patients. Roberts JA; Webb SA; Lipman J Int J Antimicrob Agents; 2007 Feb; 29(2):117-28. PubMed ID: 17158033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]